Radionetics Oncology has entered into a strategic agreement with Eli Lilly and Company. As part of the deal, Radionetics will receive a $140 million upfront payment. In return, Lilly gains the exclusive right to acquire Radionetics for $1 billion. The agreement focuses on enhancing Lilly's cancer drug pipeline with radiopharmaceuticals developed by Radionetics. Lilly inks the deal with the biotech startup to expand its radiopharmaceutical offerings.
.@EliLillyandCo strikes deal to get more #radiopharmaceuticals for its #cancer drug pipeline. $LLY is paying $140M for exclusive right to acquire #startup Radionetics #Oncology. If Lilly exercises that right, purchase price would be $1B. https://t.co/1luplCAAKU
Lilly inks radiopharma deal with Radionetics, with rights to buy the biotech https://t.co/v7AItDjEwq #biotech #news
Radiopharmaceutical startup Radionetics is getting $140 million upfront, while Lilly gets the option to acquire Radionetics for $1 billion $LLY https://t.co/6xd7hQ9RNq
Radionetics Oncology Enters Strategic Agreement With Lilly; Receives $140M Upfront Payment; Lilly Gains Exclusive Right To Acquire Radionetics For $1B $LLY
Radionetics Oncology Enters Into Strategic Agreement With Lilly https://t.co/4KOG3bwoos https://t.co/Qv681NZQOz